Farther Finance Advisors’s Pliant Therapeutics PLRX Stock Holding History

Farther Finance Advisors’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6	Hold	5	–	–	﹤0.01%	5944
2026 Q1	$7	Hold	5	–	–	﹤0.01%	5704
2025 Q4	$6	Hold	5	–	–	﹤0.01%	5425
2025 Q3	$7	Hold	5	–	–	﹤0.01%	4931
2025 Q2	$6	Hold	5	–	–	﹤0.01%	4466
2025 Q1	$7	Sell	5 -1	-17%	-$6	﹤0.01%	4231
2024 Q4	$79	Hold	6	–	–	﹤0.01%	3819
2024 Q3	$67	Hold	6	–	–	﹤0.01%	3837
2024 Q2	$65	Hold	6	–	–	﹤0.01%	3661
2024 Q1	$89	Hold	6	–	–	﹤0.01%	3398
2023 Q4	$109	Buy	+6	New	+$91	﹤0.01%	3293

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Farther Finance Advisors's PLRX Position: Q2 2026 in Review

Farther Finance Advisors held its Pliant Therapeutics (PLRX) position steady in Q2 2026 at 5 shares worth $6. The position accounts for ﹤0.01% of the portfolio, ranked #5944.

Farther Finance Advisors first reported a position in PLRX in Q4 2023 and has held it in 11 quarters since. The position peaked at $109 in Q4 2023. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

Farther Finance Advisors held 5 shares of Pliant Therapeutics worth $6 as of Q2 2026.
Farther Finance Advisors left its Pliant Therapeutics share count unchanged in Q2 2026.
Pliant Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5944 holding.
Farther Finance Advisors first reported a position in Pliant Therapeutics in Q4 2023 and has held it in 11 quarters since.
Farther Finance Advisors's Pliant Therapeutics position peaked at $109 in Q4 2023.
86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.